Suchergebnisse - "Cantini, Fabrizio"

PubPharm (209)

31

Therapeutic Potential of Ixekizumab in the Treatment of Ankylosing Spondylitis : A Review on the Emerging Clinical Data

enthalten in: Therapeutics and clinical risk management | 2020

von Benucci, M. | Damiani, A. | Li Gobbi, F. | +5

32

Non-medical switching : save today and pay tomorrow

enthalten in: Journal of medical economics | 2019

von Benucci, M. | Cantini, F.

CommentOn: J Med Econ. 2019 Nov;22(11):1162-1170. - PMID 31373527

33

Biosimilars for the treatment of psoriatic arthritis

enthalten in: Expert review of clinical immunology | 2019

von Cantini, F. | Benucci, M. | Li Gobbi, F. | +2

34

Remission maintenance after tocilizumab dose-tapering and interruption in patients with giant cell arteritis : an open-label, 18-month, prospective, pilot study

enthalten in: Annals of the rheumatic diseases | 2019

von Nannini, C. | Niccoli, L. | Sestini, S. | +3

CommentIn: Ann Rheum Dis. 2021 Nov;80(11):e184. - PMID 31690621

35

Radiologist-rheumatologist multidisciplinary approach in the management of axial spondyloarthritis : a Delphi consensus statement

enthalten in: Clinical and experimental rheumatology | 2019

von Marchesoni, A. | D'Angelo, S. | Anzidei, M. | +31

36

Characterization of QuantiFERON-TB-Plus results in latent tuberculosis infected patients with or without immune-mediated inflammatory diseases

enthalten in: The Journal of infection | 2019

von Chiacchio, T. | Petruccioli, E. | Vanini, V. | +11

37

Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice

enthalten in: Expert opinion on drug safety | 2019

von Cantini, F. | Niccoli, L. | Capone, A. | +2

38

Additional comment to : 'Switching from the bio-originators to biosimilar: is it premature to recommend this procedure?' by Scherlinger and Schaeverbeke

enthalten in: Annals of the rheumatic diseases | 2019

von Cantini, F. | Benucci, M.

CommentOn: Ann Rheum Dis. 2018 Feb;77(2):165-174. - PMID 28866648

39

Switching from the bio-originators to biosimilar : is it premature to recommend this procedure?

enthalten in: Annals of the rheumatic diseases | 2019

von Cantini, F. | Benucci, M.

CommentOn: Ann Rheum Dis. 2018 Feb;77(2):165-174. - PMID 28866648

40

Effectiveness of Adalimumab for the Treatment of Psoriatic Arthritis : An Italian Real-Life Retrospective Study

enthalten in: Frontiers in pharmacology | 2019

von D'Angelo, S. | Cantini, F. | Ramonda, R. | +29